BCRX Q3 2022 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$76M+85.0% YoY

Gross Profit

$72M95.2% margin

Operating Income

-$17M-23.0% margin

Net Income

-$43M-56.1% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+15.7%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$33M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$559M

Total Liabilities

$801M

Stockholders' Equity

-$243M

Cash & Equivalents

$247M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$76M	$41M	+85.0%
Gross Profit	$72M	$40M	+78.8%
Operating Income	-$17M	-$45M	+60.9%
Net Income	-$43M	-$59M	+27.7%

Revenue Segments

Product

$75M99%

Royalty

$600,0001%

Collaborative and Other Research and Development

$14,0000%